IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Dose escalation study to evaluate the safety, tolerability and anti-tumor activity of single
agent IMU-935 in patients with progressive, metastatic castration resistant prostate cancer
(mCRPC).